Amendment 2026-1623s to HB1772 (2026)

(New Title) relative to prescribing ibogaine for investigational use only.


Revision: April 22, 2026, 11:34 a.m.

Senate Health and Human Services

April 22, 2026

2026-1623s

05/09

 

 

Amendment to HB 1772-FN-A

 

Amend the bill by replacing section 1 with the following:  

 

1  New Section; Ibogaine; Administered Under FDA-approved Research Protocol.  Amend RSA 329 by inserting after section RSA 329:1-h the following new section:  

329:1-i Ibogaine; Administered Under FDA-approved Research Protocol. To the extent allowable by federal law, licensed physicians or qualified licensed practitioners may administer ibogaine under the framework of an FDA-approved research protocol.

2026-1623s

AMENDED ANALYSIS

 

This bill permits licensed health care providers to administer ibogaine under the framework of an FDA-approved research protocol.